TRNS vs. TXG, CTKB, LAB, EYPT, SENS, ALNT, AEHR, QTRX, QSI, and NAUT
Should you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Cytek Biosciences (CTKB), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Senseonics (SENS), Allient (ALNT), Aehr Test Systems (AEHR), Quanterix (QTRX), Quantum-Si (QSI), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.
Transcat vs.
10x Genomics (NASDAQ:TXG) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 10.0% of 10x Genomics shares are held by company insiders. Comparatively, 2.3% of Transcat shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Transcat has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
Transcat received 155 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 66.88% of users gave Transcat an outperform vote while only 52.38% of users gave 10x Genomics an outperform vote.
10x Genomics currently has a consensus target price of $23.86, suggesting a potential upside of 61.09%. Transcat has a consensus target price of $130.25, suggesting a potential upside of 30.90%. Given 10x Genomics' higher possible upside, analysts plainly believe 10x Genomics is more favorable than Transcat.
Transcat has a net margin of 6.63% compared to 10x Genomics' net margin of -28.93%. Transcat's return on equity of 7.36% beat 10x Genomics' return on equity.
10x Genomics has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
In the previous week, 10x Genomics and 10x Genomics both had 5 articles in the media. Transcat's average media sentiment score of 0.84 beat 10x Genomics' score of 0.50 indicating that Transcat is being referred to more favorably in the news media.
Summary
Transcat beats 10x Genomics on 12 of the 18 factors compared between the two stocks.
Get Transcat News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transcat Competitors List
Related Companies and Tools
This page (NASDAQ:TRNS) was last updated on 1/25/2025 by MarketBeat.com Staff
Free TRNS Stock Alerts